Dr. Ajay Bhatnagar on Why Brachytherapy Is Central to Understanding Cost, Outcomes, and Decision-Making in Prostate Cancer Care

The growing complexity of prostate cancer care has introduced a wider range of clinically accepted treatment pathways, each with distinct implications for cure rates, side effects, recovery, and quality of life. With multiple established options carrying different implications for these outcomes, the decision-making process often extends beyond diagnosis alone. According to Dr. Ajay Bhatnagar, founder of the Prostate Cancer Institute of America, this environment places greater emphasis on clear patient education and informed decision-making.

From his perspective, one of the most persistent misconceptions in prostate cancer care relates to how patients interpret value. He explains that many individuals associate higher cost with better outcomes, an assumption that can shape expectations before clinical discussions even begin. “The biggest misconception is that patients think the more expensive the treatment, the better it must be,” he says. “In reality, some of the most effective treatments are also among the most efficient.”

Clinical research offers additional context for this discussion. A study published examining long-term outcomes after low-dose-rate brachytherapy reported that at 15 years following treatment, overall survival was 81% and prostate cancer-specific survival was 95%. He believes that these findings highlight the quality of life associated with brachytherapy, reinforcing its role as a clinically relevant option in localized prostate cancer care. 

Research shows that the trends in utilization of the different radiation modalities for the treatment of men with localized prostate cancer revealed a significant increase in the use of Intensity Modulated Radiation Therapy. 

Dr. Bhatnagar emphasizes that the implications of these patterns are often felt most directly by patients. He explains that individuals frequently encounter conflicting recommendations and are left to navigate a range of options that may appear similar in terms of cure rates but differ in side effects and logistics. “There is a lot of noise,” he says. “Patients are trying to make decisions in an environment where the information can feel overwhelming.”

Within his own practice, Dr. Bhatnagar approaches this challenge by focusing on prostate brachytherapy as a core area of specialization, offering targeted radiation techniques designed to treat the prostate while limiting exposure to surrounding tissue. He explains that this approach is supported by a broader effort to guide patients through their options, helping them understand how different treatments align with their individual priorities, recovery expectations, and long-term quality-of-life considerations.

According to Dr. Bhatnagar, this complexity is particularly evident in early-stage prostate cancer, where treatment decisions are rarely straightforward. He notes that some patients assume surgery is the only viable option, while others may believe that delaying treatment carries little risk. He explains that both assumptions can limit how patients engage with their choices, especially when they are not fully aware of the full spectrum of available treatments.

Clinical research examining emerging radiation technologies in prostate cancer care has contributed to ongoing discussion within the medical community. Findings from a phase III randomized trial reported no significant difference in progression-free survival between proton therapy and intensity-modulated radiation therapy, with five-year rates of 93.4 percent and 93.7 percent, respectively. Earlier cost analyses have also reported substantial differences in treatment costs, with proton therapy estimated at $115,501 compared to $59,012 for IMRT. Together, he notes that these findings have informed broader conversations about how treatment value is evaluated in clinical practice.

For Dr. Bhatnagar, improving clarity in these conversations is a priority. He explains that patients benefit from understanding not only the clinical aspects of each treatment, but also how those options align with their individual goals and quality-of-life considerations. In his view, access to clear and balanced information can help patients move from uncertainty toward more confident decision-making.

He notes that this emphasis on education has also informed his contribution to clinical literature, including his book Modern Low Dose Rate Brachytherapy for Prostate Cancer: A Comprehensive Guide for Urologists, which brings together practical guidance on treatment techniques, patient selection, and evolving best practices. 

He explains that resources like this are intended to support more informed discussions between physicians and patients, particularly in areas where treatment choices can be difficult to navigate. From his perspective, strengthening this knowledge base can help ensure that clinically relevant options remain accessible within a rapidly evolving treatment landscape. 

As discussions around value-based care continue to evolve, the focus remains on aligning treatment decisions with outcomes, patient experience, and efficiency. Dr. Bhatnagar believes that increasing awareness of prostate brachytherapy, alongside broader educational efforts, can contribute to a more informed approach to prostate cancer care. “Patients deserve to understand all of their options,” he says. “When they do, they are in a much better position to choose what is right for them.”

This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.